Fluoxetine 25 MG / olanzapine 3 MG Oral Capsule — RxCUI 721787
RxNorm drug concept · Semantic clinical drug
RxCUI 721787
Semantic clinical drug · SCD
● Current RxNorm concept 15 FDA products
15 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI721787
Official nameFluoxetine 25 MG / olanzapine 3 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asfluoxetine 25 MG (as fluoxetine hydrochloride) / olanzapine 3 MG Oral Capsule; OLANZapine 3 MG / FLUoxetine HCl 25 MG Oral Capsule
FDA products mapped15
Package NDCs mapped15
Reported Medicaid activity (SDUD)5,161 prescriptions · 18 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Olanzapine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It treats schizophrenia and manic or mixed episodes of bipolar I disorder, and can be added to lithium or valproate. An injection form is used for sudden agitation with those condi...
- Oral olanzapine is usually taken once a day, with or without food. Take it as your prescriber directs and don’t stop on your own. Injections are given by a healthcare professional.
- Sleepiness, dizziness, dry mouth, constipation, increased appetite and weight gain are common. Stand up slowly, especially at first. Your prescriber will check blood sugar, cholest...
- Call right away for fever with stiff muscles or confusion, a severe rash, fainting, seizures, uncontrolled movements, extreme thirst or urination, or thoughts of self-harm.
🕸️ Concept Web — How Fluoxetine 25 MG / olanzapine 3 MG Oral Capsule Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Fluoxetine 25 MG / olanzapine 3 MG Oral Capsule
RxCUI 721787 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 3
The active substance itself — no strength, form, or brand attached yet.
-
Fluoxetine
4493IN -
Olanzapine
61381IN -
Fluoxetine / olanzapine
611247MIN
-
Fluoxetine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Symbyax
405343BN
-
Symbyax
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Fluoxetine / olanzapine Oral Capsule
406024SCDF -
Fluoxetine / olanzapine Oral Product
1160833SCDG -
Fluoxetine / olanzapine Pill
1160834SCDG -
Fluoxetine / olanzapine Oral Capsule [Symbyax]
725063SBDF -
Symbyax Oral Product
1185498SBDG -
Symbyax Pill
1185499SBDG -
Oral Capsule
316965DF -
Oral Product
1151131DFG - +1 more in this family
-
Fluoxetine / olanzapine Oral Capsule
-
Clinical & branded drugs 4
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Fluoxetine 25 MG
406022SCDC -
Olanzapine 3 MG
721786SCDC -
Fluoxetine 25 MG / olanzapine 3 MG Oral Capsule [Symbyax]
725080SBD -
Fluoxetine 25 MG / olanzapine 3 MG [Symbyax]
725078SBDC
-
Fluoxetine 25 MG
Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Fluoxetine 25 MG
SCDC · 406022 -
Olanzapine 3 MG
SCDC · 721786 -
Fluoxetine / olanzapine Oral Capsule
SCDF · 406024 -
Fluoxetine / olanzapine Oral Product
SCDG · 1160833 -
Fluoxetine / olanzapine Pill
SCDG · 1160834
Brand-Name Concepts
-
Fluoxetine 25 MG / olanzapine 3 MG Oral Capsule [Symbyax]
SBD · 725080 -
Fluoxetine 25 MG / olanzapine 3 MG [Symbyax]
SBDC · 725078 -
Fluoxetine / olanzapine Oral Capsule [Symbyax]
SBDF · 725063 -
Symbyax Oral Product
SBDG · 1185498 -
Symbyax Pill
SBDG · 1185499 -
Symbyax
BN · 405343
📦 FDA Products & Package NDCs
15 products · 15 package NDCs
15 package NDCs map to RxCUI 721787 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00093-5503-56 | 30 CAPSULE in 1 BOTTLE (0093-5503-56) | Olanzapine and Fluoxetine | Teva Pharmaceuticals USA, Inc. | 2013-04-10 |
| 00093-5504-56 | 30 CAPSULE in 1 BOTTLE (0093-5504-56) | Olanzapine and Fluoxetine | Teva Pharmaceuticals USA, Inc. | 2012-06-19 |
| 00093-5505-56 | 30 CAPSULE in 1 BOTTLE (0093-5505-56) | Olanzapine and Fluoxetine | Teva Pharmaceuticals USA, Inc. | 2012-06-19 |
| 00093-5506-56 | 30 CAPSULE in 1 BOTTLE (0093-5506-56) | Olanzapine and Fluoxetine | Teva Pharmaceuticals USA, Inc. | 2012-06-19 |
| 00093-5507-56 | 30 CAPSULE in 1 BOTTLE (0093-5507-56) | Olanzapine and Fluoxetine | Teva Pharmaceuticals USA, Inc. | 2012-06-19 |
| 42291-0652-30 | 30 CAPSULE in 1 BOTTLE (42291-652-30) | Olanzapine and Fluoxetine | AvKARE | 2014-01-21 |
| 42291-0653-30 | 30 CAPSULE in 1 BOTTLE (42291-653-30) | Olanzapine and Fluoxetine | AvKARE | 2014-01-21 |
| 42291-0654-30 | 30 CAPSULE in 1 BOTTLE (42291-654-30) | Olanzapine and Fluoxetine | AvKARE | 2014-01-21 |
| 42291-0655-30 | 30 CAPSULE in 1 BOTTLE (42291-655-30) | Olanzapine and Fluoxetine | AvKARE | 2014-01-21 |
| 42291-0656-30 | 30 CAPSULE in 1 BOTTLE (42291-656-30) | Olanzapine and Fluoxetine | AvKARE | 2014-01-21 |
| 49884-0250-11 | 30 CAPSULE in 1 BOTTLE, PLASTIC (49884-250-11) | Olanzapine and Fluoxetine | Par Health USA, LLC | 2012-11-26 |
| 49884-0251-11 | 30 CAPSULE in 1 BOTTLE, PLASTIC (49884-251-11) | Olanzapine and Fluoxetine | Par Health USA, LLC | 2012-11-26 |
| 49884-0252-11 | 30 CAPSULE in 1 BOTTLE, PLASTIC (49884-252-11) | Olanzapine and Fluoxetine | Par Health USA, LLC | 2012-11-26 |
| 49884-0253-11 | 30 CAPSULE in 1 BOTTLE, PLASTIC (49884-253-11) | Olanzapine and Fluoxetine | Par Health USA, LLC | 2012-11-26 |
| 49884-0277-11 | 30 CAPSULE in 1 BOTTLE, PLASTIC (49884-277-11) | Olanzapine and Fluoxetine | Par Health USA, LLC | 2012-11-26 |
Observed labelers:
AvKARE (5) ·
Par Health USA, LLC (5) ·
Teva Pharmaceuticals USA, Inc. (5)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.